

Supplemental Material

Long-term mortality in hypertensive patients with coronary artery disease: Results from the United States cohort of the INternational VERapamil/Trandolapril Study

Islam Y. Elgendy, MD; Anthony A. Bavry, MD, MPH; Yan Gong, PhD; Eileen M. Handberg, PhD; Rhonda M. Cooper-DeHoff, PharmD, MS ; Carl J. Pepine, MD

From the Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida (I.Y.E., A.A.B., R.M.C, C.J.P.), North Florida/South Georgia Veterans Health System, Gainesville, Florida (A.A.B.), and the Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville, Florida.

Correspondence:

Islam Y. Elgendy, MD

Division of Cardiovascular Medicine, Department of Medicine


College of Medicine, University of Florida, PO Box 100277

1600 SW Archer Road, Gainesville, FL 32610, USA

Email: islam.elgendy@medicine.ufl.edu

Telephone: 352-273-9089, Fax: 352-392-3606

All cause mortality in Extended Followup in US



Kaplan-Meier curves for all-cause mortality in both the beta-blocker based strategy (green) and the calcium antagonist based strategy (red).

BB= beta-blocker; CA= calcium antagonist